Related Experiment Video
Updated: Dec 20, 2025
High-Throughput Screening of Microbial Isolates with Impact on Caenorhabditis elegans Health
Published on: April 28, 2022
Anti-MRSA agent discovery using Caenorhabditis elegans-based high-throughput screening
Soo Min Kim1, Iliana Escorbar2, Kiho Lee2
1College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, 03760, Republic of Korea.
Abstract:
Staphylococcus aureus is a leading cause of hospital- and community-acquired infections. Despite current advances in antimicrobial chemotherapy, the infections caused by S. aureus remain challenging due to their ability to readily develop resistance. Indeed, antibiotic resistance, exemplified by methicillin-resistant S. aureus (MRSA) is a top threat to global health security. Furthermore, the current rate of antibiotic discovery is much slower than the rate of antibiotic-resistance development. It seems evident that the conventional in vitro bacterial growth-based screening strategies can no longer effectively supply new antibiotics at the rate needed to combat bacterial antibiotic-resistance. To overcome this antibiotic resistance crisis, screening assays based on host-pathogen interactions have been developed. In particular, the free-living nematode Caenorhabditis elegans has been used for drug screening against MRSA. In this review, we will discuss the general principles of the C. elegans-based screening platform and will highlight its unique strengths by comparing it with conventional antibiotic screening platforms. We will outline major hits from high-throughput screens of more than 100,000 small molecules using the C. elegans-MRSA infection assay and will review the mode-of-action of the identified hit compounds. Lastly, we will discuss the potential of a C. elegans-based screening strategy as a paradigm shift screening platform.
Insights
The nematode Caenorhabditis elegans offers a novel platform for discovering new antibiotics against drug-resistant bacteria like methicillin-resistant Staphylococcus aureus (MRSA). This host-pathogen model overcomes limitations of traditional methods, accelerating the fight against antibiotic resistance.
Area of Science:
- Microbiology and Infectious Diseases
- Drug Discovery and Pharmacology
- Genetics and Molecular Biology
Background:
- Staphylococcus aureus infections, including methicillin-resistant S. aureus (MRSA), pose a significant global health threat due to widespread antibiotic resistance.
- Conventional in vitro antibiotic screening methods are insufficient to keep pace with the rapid development of bacterial resistance.
- There is an urgent need for novel strategies to discover new antibiotics effective against resistant pathogens.
Purpose of the Study:
- To review the principles and advantages of using Caenorhabditis elegans as a host-pathogen model for antibiotic drug screening.
- To highlight the potential of C. elegans-based screening platforms in combating antibiotic resistance.
- To discuss findings from high-throughput screens using this model.
Main Methods:
- Utilizing the nematode Caenorhabditis elegans as a model host for Staphylococcus aureus infection.
- Implementing high-throughput screening of small molecules in a C. elegans-MRSA infection assay.
- Comparing the efficacy and strengths of the C. elegans platform against conventional antibiotic screening methods.
Main Results:
- Identification of numerous hit compounds from large-scale screens (>100,000 small molecules) against MRSA using the C. elegans model.
- Analysis of the modes of action for compounds identified through the C. elegans-based screening.
- Demonstration of the C. elegans platform's unique strengths in identifying potential anti-MRSA agents.
Conclusions:
- The Caenorhabditis elegans-based screening strategy represents a promising paradigm shift for antibiotic discovery.
- This host-pathogen model accelerates the identification of novel therapeutic compounds against challenging bacterial infections.
- The C. elegans platform offers a viable solution to the growing crisis of antibiotic resistance.
